Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety
Overview
Paper Summary
Ozanimod and etrasimod, two new drugs for ulcerative colitis, work by stopping lymphocytes from reaching the inflamed colon, leading to reduced inflammation and improved symptoms. While clinical trials indicate a manageable safety profile, potential for cardiovascular, ocular, hepatic, pulmonary, and infectious complications necessitates precautions and careful monitoring.
Explain Like I'm Five
Two new medications, ozanimod and etrasimod, help treat ulcerative colitis by keeping lymphocytes from traveling to the inflamed colon. Studies show they're generally safe, but some heart, eye, liver, or lung problems are possible.
Possible Conflicts of Interest
Massimo C. Fantini and Diego Centonze have acted as paid consultants and/or advisory board members for several pharmaceutical companies, including Pfizer, the funder of this review. Giovanni Giacobazzi and Silvia Benemei are Pfizer employees. Emanuele Romeo was a paid consultant to Pfizer.
Identified Limitations
Rating Explanation
This review provides a good overview of ozanimod and etrasimod for ulcerative colitis, including mechanism of action and safety profile based on current evidence. While generally safe, the potential for several types of side effects requires vigilance. The authors acknowledge limitations like limited long-term data and the need for head-to-head comparisons, improving the transparency and trustworthiness. However, the multiple COIs warrant a slightly lower rating.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →